Showing 421 - 440 results of 114,422 for search '(( 5 ((((ng decrease) OR (nn decrease))) OR (a decrease)) ) OR ( a non decrease ))', query time: 1.51s Refine Results
  1. 421
  2. 422

    HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching. by Michael Anthony Ruiz (726055)

    Published 2015
    “…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
  3. 423
  4. 424

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  5. 425
  6. 426
  7. 427
  8. 428
  9. 429

    A summary of the included study characteristics. by Zahra Tajik (20752452)

    Published 2025
    “…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 430
  11. 431
  12. 432
  13. 433
  14. 434
  15. 435

    DataSheet2_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.pdf by Sunil Veeravalli (5074115)

    Published 2022
    “…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
  16. 436

    DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF by Sunil Veeravalli (5074115)

    Published 2022
    “…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
  17. 437
  18. 438
  19. 439
  20. 440